Paclitaxel-eluting stents: current clinical experience

Area of Science:

• Interventional Cardiology
• Biomaterials Science
• Pharmacology

Background:

• Drug-eluting stents (DES) are a key innovation in interventional cardiology, aiming to reduce restenosis.
• Paclitaxel-eluting stents (PES) are commercially available and effective, but outcomes vary due to stent design and drug delivery.
• Directly impregnated PES systems have shown mixed results, with significant benefits only in high-dose groups.

Purpose of the Study:

• To evaluate the safety and efficacy of polymer-based, paclitaxel-eluting stents (PES) with controlled drug release.
• To compare the performance of the TAXUS PES system against directly impregnated PES and uncoated stents.
• To assess the effectiveness of TAXUS stents in diverse patient and lesion subsets.

Main Methods:

• Clinical investigations including multicenter trials (ASPECT, ELUTES, DELIVER I, TAXUS I, II, IV).
• Evaluation of stent platforms, drug load, and drug delivery/release concepts.
• Analysis of restenosis rates, neointimal proliferation, and clinical endpoints in various patient populations.

Main Results:

• Directly impregnated PES showed dose-response but limited significant reduction in restenosis.
• The TAXUS polymer-based PES demonstrated safety and reduced in-stent restenosis.
• TAXUS stents proved safe and effective in reducing restenosis in larger populations and complex lesions.

Conclusions:

• Polymer-based, controlled-release TAXUS PES offer a safe and effective alternative to directly impregnated stents.
• TAXUS stents show significant efficacy in reducing restenosis across various clinical scenarios.
• Ongoing studies and registries are crucial for long-term monitoring of drug-eluting stent performance.